Mettler-Toledo International Inc. — Q1 2021 Form 10-Q
Business context and reporting period. The company supplies precision instruments and related services across laboratory, industrial, food retail, packaging, logistics and process analytics markets. This unaudited report covers the three months ended March 31, 2021, compared with the same period in 2020. Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions where shown.
Financial performance
| Metric | Q1 2021 | Q1 2020 | Change / context |
|---|---|---|---|
| Net sales | $804.4 million | $649.2 million | Up 24% reported; up 18% in local currencies |
| Gross profit / margin | $471.7 million / 58.6% | $374.4 million / 57.7% | Margin up 0.9 percentage points |
| Earnings before taxes | $185.4 million | $118.5 million | Up approximately 56% |
| Net earnings | $149.7 million | $98.1 million | Up approximately 53% |
| Diluted EPS | $6.32 | $4.03 | Up approximately 57% |
| Operating cash flow | $158.9 million | $65.5 million | Higher earnings, working capital and tax-payment timing contributed |
| Capital expenditures | $24.6 million | $18.8 million | Increased year over year |
Product sales rose 28% in reported dollars and 23% in local currency; service revenue, including spare parts, rose 11% and 6%, respectively. Gross margin improvement reflected higher volume and favorable pricing, partly offset by increased transportation and material costs. SG&A was 27.6% of sales versus 30.6% a year earlier; R&D was 4.9% versus 5.3%.
Balance sheet, liquidity and capital allocation
- At March 31, 2021, cash and cash equivalents were $106.7 million. Total debt was $1.614 billion, including $52.5 million current and $1.561 billion long-term; debt increased mainly to fund the PendoTECH acquisition.
- The company reported $460.7 million of additional borrowing capacity under its credit agreement and said operating cash flow, available credit and cash should cover anticipated working-capital and capital-spending needs for the foreseeable future. It was in compliance with debt covenants.
- Current assets were $1.080 billion and current liabilities $841.8 million. Shareholders’ equity was $202.6 million, down from $282.7 million at year-end 2020.
- Operating cash flow was partly offset by $191.5 million of investing cash outflow, including the $185.0 million PendoTECH cash purchase, and $262.5 million of share repurchases. Repurchases covered 224,808 shares at an average $1,167.64; $2.796 billion remained available under the program.
Material changes and unusual items
- In March, the company acquired PendoTECH, a U.S. supplier of single-use bioprocess sensors, systems and software. The initial cash payment was $185.0 million; additional consideration of up to $20.0 million may be payable based on 2022–2023 financial thresholds. The acquisition added $93.7 million of goodwill and $106.1 million of identified intangible assets; estimated annual amortization for acquired finite-life intangibles is $6.9 million.
- Q1 2021 other charges included $2.8 million of acquisition costs. The prior-year comparison included a net $3.3 million of other income, versus $0.7 million of other charges in Q1 2021; this line includes foreign-exchange and hedging effects, pension items and other items.
- China’s external sales grew 44% in local currency, but management noted the comparison benefited from COVID-related weakness in Q1 2020 and expected tougher comparisons during the rest of 2021. Laboratory sales also benefited from biopharma activity and COVID-19 testing and vaccine development/production.
Outlook, commentary and risks
The filing provides no specific full-year revenue or EPS guidance. Management expects 2021 net investments in new or expanded manufacturing facilities of $10–15 million and continues to explore acquisitions, which could add debt. Management described operations and supply chains as functioning with minimal interruption, while cautioning that COVID-19 and global economic conditions remain uncertain and can change quickly.
- Foreign-exchange exposure: management estimates a 1% strengthening of the Swiss franc against the euro would reduce annual pretax earnings by about $1.6–$1.8 million; a 1% weakening of the Chinese renminbi against the U.S. dollar would reduce annual pretax earnings by about $2.3–$2.5 million. A 5% weakening of the U.S. dollar against debt currencies would increase the reported U.S.-dollar debt value by about $33.3 million.
- Other stated risks include COVID-19’s duration and economic effects, demand changes, pricing, supply-chain and shipping costs, raw-material availability, currencies, and acquisition outcomes. Management reported no material change in disclosed risk factors and no expected material adverse effect from pending legal proceedings.
- Restructuring charges were $1.2 million, versus $1.9 million in Q1 2020. The company also recorded a $13.5 million estimated fair value liability for PendoTECH contingent consideration, based on significant unobservable assumptions.
Important facts for investors to verify
- Whether sales and margin growth persist as COVID-related comparisons normalize, particularly in China and laboratory markets.
- PendoTECH’s subsequent performance, integration, amortization impact and potential contingent payments.
- Debt levels, borrowing capacity and the balance between acquisitions and the $262.5 million quarterly repurchase pace.
- Cash conversion and working-capital trends, including inventory, deferred revenue and the effects of tax-payment timing.
- Exposure to currency movements, transportation and material costs, and continuing pandemic-related market uncertainty.